Literature DB >> 21248069

Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.

Yingming Li1, Majid Alsagabi, Danhua Fan, G Steven Bova, Ahmed H Tewfik, Scott M Dehm.   

Abstract

Androgen depletion for advanced prostate cancer (PCa) targets activity of the androgen receptor (AR), a steroid receptor transcription factor required for PCa growth. The emergence of lethal castration-resistant PCa (CRPCa) is marked by aberrant reactivation of the AR despite ongoing androgen depletion. Recently, alternative splicing has been described as a mechanism giving rise to COOH-terminally truncated, constitutively active AR isoforms that can support the CRPCa phenotype. However, the pathologic origin of these truncated AR isoforms is unknown. The goal of this study was to investigate alterations in AR expression arising in a cell-based model of PCa progression driven by truncated AR isoform activity. We show that stable, high-level expression of truncated AR isoforms in 22Rv1 CRPCa cells is associated with intragenic rearrangement of an approximately 35-kb AR genomic segment harboring a cluster of previously described alternative AR exons. Analysis of genomic data from clinical specimens indicated that related AR intragenic copy number alterations occurred in CRPCa in the context of AR amplification. Cloning of the break fusion junction in 22Rv1 cells revealed long interspersed nuclear elements (LINE-1) flanking the rearranged segment and a DNA repair signature consistent with microhomology-mediated, break-induced replication. This rearrangement served as a marker for the emergence of a rare subpopulation of CRPCa cells expressing high levels of truncated AR isoforms during PCa progression in vitro. Together, these data provide the first report of AR intragenic rearrangements in CRPCa and an association with pathologic expression of truncated AR isoforms in a cell-based model of PCa progression. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248069      PMCID: PMC3059379          DOI: 10.1158/0008-5472.CAN-10-1998

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Using RepeatMasker to identify repetitive elements in genomic sequences.

Authors:  Maja Tarailo-Graovac; Nansheng Chen
Journal:  Curr Protoc Bioinformatics       Date:  2009-03

2.  Androgen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor.

Authors:  Ayush Dagvadorj; Shyh-Han Tan; Zhiyong Liao; Luciane R Cavalli; Bassem R Haddad; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

3.  Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.

Authors:  Margaret A Leversha; Jialian Han; Zahra Asgari; Daniel C Danila; Oscar Lin; Rita Gonzalez-Espinoza; Aseem Anand; Hans Lilja; Glenn Heller; Martin Fleisher; Howard I Scher
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

4.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.

Authors:  Scott M Dehm; Lucy J Schmidt; Hannelore V Heemers; Robert L Vessella; Donald J Tindall
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 5.  Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex.

Authors:  Hannelore V Heemers; Donald J Tindall
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

6.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

Authors:  Rong Hu; Thomas A Dunn; Shuanzeng Wei; Sumit Isharwal; Robert W Veltri; Elizabeth Humphreys; Misop Han; Alan W Partin; Robert L Vessella; William B Isaacs; G Steven Bova; Jun Luo
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

7.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

Authors:  Zhiyong Guo; Xi Yang; Feng Sun; Richeng Jiang; Douglas E Linn; Hege Chen; Hegang Chen; Xiangtian Kong; Jonathan Melamed; Clifford G Tepper; Hsing-Jien Kung; Angela M H Brodie; Joanne Edwards; Yun Qiu
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

8.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Joost F Swennenhuis; David Olmos; Alison H M Reid; Elaine Vickers; Roger A'Hern; Rianne Levink; Frank Coumans; Joana Moreira; Ruth Riisnaes; Nikhil Babu Oommen; George Hawche; Charles Jameson; Emilda Thompson; Ronald Sipkema; Craig P Carden; Christopher Parker; David Dearnaley; Stan B Kaye; Colin S Cooper; Arturo Molina; Michael E Cox; Leon W M M Terstappen; Johann S de Bono
Journal:  Cancer Res       Date:  2009-04-01       Impact factor: 12.701

Review 9.  Mammalian non-LTR retrotransposons: for better or worse, in sickness and in health.

Authors:  Victoria P Belancio; Dale J Hedges; Prescott Deininger
Journal:  Genome Res       Date:  2008-02-06       Impact factor: 9.043

Review 10.  A microhomology-mediated break-induced replication model for the origin of human copy number variation.

Authors:  P J Hastings; Grzegorz Ira; James R Lupski
Journal:  PLoS Genet       Date:  2009-01-30       Impact factor: 5.917

View more
  112 in total

1.  Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.

Authors:  Ziyue Karen Jiang; Makoto Sato; Liu H Wei; Chinghai Kao; Lily Wu
Journal:  Cancer Res       Date:  2011-09-20       Impact factor: 12.701

Review 2.  Potential molecular targeting of splice variants for cancer treatment.

Authors:  Christopher A Blair; Xiaolin Zi
Journal:  Indian J Exp Biol       Date:  2011-11       Impact factor: 0.818

Review 3.  Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Authors:  Cameron M Armstrong; Allen C Gao
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

Review 4.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

5.  Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.

Authors:  Puranik Purushottamachar; Andrew K Kwegyir-Afful; Marlena S Martin; Vidya P Ramamurthy; Senthilmurugan Ramalingam; Vincent C O Njar
Journal:  ACS Med Chem Lett       Date:  2016-05-23       Impact factor: 4.345

6.  Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.

Authors:  Siu Chiu Chan; Yingming Li; Scott M Dehm
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

Review 7.  Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Authors:  Kathryn E Ware; Mariano A Garcia-Blanco; Andrew J Armstrong; Scott M Dehm
Journal:  Endocr Relat Cancer       Date:  2014-05-23       Impact factor: 5.678

8.  Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.

Authors:  Ayesha A Shafi; Marc B Cox; Nancy L Weigel
Journal:  Steroids       Date:  2013-02-01       Impact factor: 2.668

Review 9.  Constitutive activity of the androgen receptor.

Authors:  Siu Chiu Chan; Scott M Dehm
Journal:  Adv Pharmacol       Date:  2014

10.  miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.

Authors:  Xu-Bao Shi; Ai-Hong Ma; Lingru Xue; Meimei Li; Hao G Nguyen; Joy C Yang; Clifford G Tepper; Regina Gandour-Edwards; Christopher P Evans; Hsing-Jien Kung; Ralph W deVere White
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.